期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 101, 期 3, 页码 283-290出版社
WILEY
DOI: 10.1111/ejh.13131
关键词
EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease
类别
资金
- National Science Foundation of China [81700173, 81730003]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), National Key R&D Program of China [2016YFC0902800]
- Innovation Capability Development Project of Jiangsu Province [BM2015004]
- Jiangsu Provincial Key Medical Center [YXZXA2016002]
Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据